Roth Capital Reaffirms TG Therapeutics (TGTX) at 'Buy'; Still Sees TGR-1202, TG-1101 as Well Positioned
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
Go back to Roth Capital Reaffirms TG Therapeutics (TGTX) at 'Buy'; Still Sees TGR-1202, TG-1101 as Well Positioned
November 7, 2016 7:34 AM EST
TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.50), $0.19 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $30 thousand.
Cash, cash equivalents, investment securities, and interest receivable were $60.7 million as of September 30, 2016.
For... More